$34.4 Million is the total value of Yu Fan's 4 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AVIR | New | ATEA PHARMACEUTICALS INC | $37,602,000 | – | 900,000 | +100.0% | 61.26% | – |
LUNG | New | PULMONX CORP | $20,915,000 | – | 303,030 | +100.0% | 34.08% | – |
AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $2,646,000 | – | 336,132 | +100.0% | 4.31% | – |
New | DIFFUSION PHARMACEUTICALS IN | $213,000 | – | 269,544 | +100.0% | 0.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CASTLE BIOSCIENCES INC | 12 | Q3 2023 | 24.7% |
ABG ACQUISITION CORP I | 8 | Q4 2022 | 83.9% |
SONENDO INC | 8 | Q3 2023 | 60.4% |
PRENETICS GLOBAL LTD | 6 | Q3 2023 | 1.9% |
DIFFUSION PHARMACEUTICALS IN | 6 | Q1 2022 | 0.8% |
CASTLE BIOSCIENCES INC | 5 | Q2 2023 | 25.8% |
APEXIGEN INC | 4 | Q2 2023 | 14.8% |
ATEA PHARMACEUTICALS INC | 3 | Q2 2021 | 61.3% |
PULMONX CORP | 2 | Q1 2021 | 36.2% |
SAGIMET BIOSCIENCES INC | 1 | Q3 2023 | 35.7% |
View Yu Fan's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Pulmonx Corp | February 11, 2022 | 31,903 | 0.1% |
View Yu Fan's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
4 | 2023-06-21 |
13F-HR | 2023-05-15 |
4 | 2023-03-15 |
4 | 2023-03-03 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View Yu Fan's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.